Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 8
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
MET exon 14 skipping
ovarian cancer · Immune Checkpoint Inhibitor
MET exon 14 skipping is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 9 contexts. FDA CDx context should be reviewed manually. Threshold text varies across public records.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: PD-L1 CPS ≥1 | PD-L1 CPS ≥10 | MSI-H
Threshold label: Fragmented
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02873962 | https://clinicaltrials.gov/study/NCT02674061 | https://clinicaltrials.gov/study/NCT04561362 | https://clinicaltrials.gov/study/NCT03410784 | https://clinicaltrials.gov/study/NCT03012620 | https://clinicaltrials.gov/study/NCT04387227 | https://clinicaltrials.gov/study/NCT05737199 | https://clinicaltrials.gov/study/NCT04417192 | https://clinicaltrials.gov/study/NCT02606305